Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) reached a new 52-week low on Thursday . The stock traded as low as $13.10 and last traded at $0.00, with a volume of shares.

Several analysts have recently weighed in on AMAG shares. Cantor Fitzgerald reaffirmed a “hold” rating and set a $21.00 price objective on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Cowen and Company reaffirmed a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Finally, Morgan Stanley cut their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $25.50.

The company has a debt-to-equity ratio of 0.94, a current ratio of 1.59 and a quick ratio of 1.41.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. The company had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. During the same period last year, the firm earned $1.45 earnings per share. The firm’s revenue was up 24.3% on a year-over-year basis. analysts expect that AMAG Pharmaceuticals, Inc. will post -1.26 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Karp Capital Management Corp bought a new position in shares of AMAG Pharmaceuticals in the first quarter valued at approximately $232,000. OppenheimerFunds Inc. lifted its holdings in shares of AMAG Pharmaceuticals by 101.1% in the 1st quarter. OppenheimerFunds Inc. now owns 17,575 shares of the specialty pharmaceutical company’s stock worth $396,000 after acquiring an additional 8,836 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of AMAG Pharmaceuticals by 1.6% in the 1st quarter. Principal Financial Group Inc. now owns 261,929 shares of the specialty pharmaceutical company’s stock worth $5,906,000 after acquiring an additional 4,008 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of AMAG Pharmaceuticals by 233.5% in the 1st quarter. Wellington Management Group LLP now owns 161,739 shares of the specialty pharmaceutical company’s stock worth $3,648,000 after acquiring an additional 113,240 shares during the last quarter. Finally, Teachers Advisors LLC lifted its holdings in shares of AMAG Pharmaceuticals by 3.6% in the 1st quarter. Teachers Advisors LLC now owns 62,055 shares of the specialty pharmaceutical company’s stock worth $1,399,000 after acquiring an additional 2,164 shares during the last quarter.

WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/amag-pharmaceuticals-inc-amag-reaches-new-52-week-low-at-13-10/1679128.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.